Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143728 | 0.77 | DRD4 (0.41) | CA2CA4CA9CCNT1CCNA2 | |
| SCHEMBL2143831 | 0.76 | PIK3CG (0.46) | CA2CA4CA9CCNA2CDK2 | |
| SCHEMBL4510261 | 0.76 | NPC1 (0.42) | CA2CA4CA9CCNA2CDK2 | |
| SCHEMBL5552478 | 0.74 | ALDH1A1 (0.41) | CA2CA4CA9CCNA2CDK2 | |
| SCHEMBL4515570 | 0.74 | CDK2 (0.41) | CCNT1CCNA2CDK2CDK9CDK1 | |
| SCHEMBL11942158 | 0.74 | ALOX5 (0.41) | CA2CA4CA9DRD4LMNA | |
| SCHEMBL5556207 | 0.73 | ALDH1A1 (0.40) | CA2CA4CA9CCNA2CDK2 | |
| SCHEMBL14817951 | 0.72 | ALDH1A1 (0.40) | CA2CA4CA9DRD4LMNA | |
| SCHEMBL2143847 | 0.72 | ALDH1A1 (0.41) | CA2CA4CA9DRD4LMNA | |
| SCHEMBL5556915 | 0.72 | ALDH1A1 (0.41) | CA2CA4CA9CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802636-B1 | PI3 KINASES INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-8232286-B2 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232286-B2 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232286-B2 | N-[1-(3-dimethylamino-4-formyl-phenyl)-3-pyridin-3-yl-4,5-dihydro-1H-pyrazolo[4,3-g]benzothiazol-7-yl]-acetamide; phosphatidylinositol-3-kinases (PI3-kinases) inhibitor; cell growth, differentiation and intracellular transport processes; antiproliferative, antiinflammatory agent; autoimmune diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-2343303-A1 | PI3-kinase inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-20090156554-A1 | P13-KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156554-A1 | P13-KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20060106013-A1 | PI3-kinases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156554-A1 | P13-KINASES | PIK3C3, PDPK1, MAP3K13 | CA2 2157/4885CA4 2368/4885CA9 2513/4885 |
| US-20060106013-A1 | PI3-kinases | PIK3C3, PIK3CB, PIK3CD | CA2 1503/4885CA4 2439/4885CA9 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.